Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Historical Holders from Q4 2018 to Q1 2025

Symbol
CLDX on Nasdaq
CUSIP
15117B202
Type / Class
Equity / Common Stock, par value $.001
Shares outstanding
67M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
73.7M
Holdings value
$1.86B
% of all portfolios
0.004%
Grand Portfolio weight change
0%
Number of holders
178
Number of buys
90
Number of sells
-83
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Kynam Capital Management, LP 7.63% $91.9M 5.06M Kynam Capital Management, LP Dec 31, 2024
FMR LLC 7.3% $88.2M 4.86M FMR LLC Dec 31, 2024
BlackRock, Inc. 7.3% -12.5% $87.5M -$12M 4.82M -12.1% BlackRock, Inc. Mar 31, 2025
PRICE T ROWE ASSOCIATES INC /MD/ 5.4% $64.6M 3.56M T. Rowe Price Associates, Inc. Dec 31, 2024
COMMODORE CAPITAL LP 5% $60.8M 3.35M COMMODORE CAPITAL LP Apr 3, 2025

Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 301K $5.43M +$739K $18.15 13
2024 Q4 73.7M $1.86B -$10.9M $25.27 178
2024 Q3 71.8M $2.44B +$61.9M $33.99 181
2024 Q2 69.6M $2.58B +$1.54M $37.01 181
2024 Q1 69.3M $2.91B +$374M $41.97 197
2023 Q4 60.3M $2.39B +$344M $39.66 159
2023 Q3 50.6M $1.39B -$662K $27.52 139
2023 Q2 50.2M $1.7B +$19.5M $33.93 147
2023 Q1 49.5M $1.78B +$25M $35.98 156
2022 Q4 48.7M $2.17B -$3.35M $44.57 160
2022 Q3 49M $1.37B +$39.8M $28.11 142
2022 Q2 48.2M $1.29B -$45.8M $26.96 145
2022 Q1 49.6M $1.68B +$106M $34.06 156
2021 Q4 43.2M $1.66B +$98.8M $38.64 168
2021 Q3 43.1M $2.31B +$390M $53.99 155
2021 Q2 35.6M $1.18B +$48M $33.44 126
2021 Q1 34.5M $709M -$32.5M $20.60 110
2020 Q4 36.3M $637M +$70.5M $17.52 116
2020 Q3 32.1M $470M +$66.7M $14.83 79
2020 Q2 27.8M $356M +$311M $13.00 61
2020 Q1 3.91M $5.82M -$78.4K $1.66 29
2019 Q4 3.9M $7.91M +$19.4K $2.23 32
2019 Q3 3.68M $7.48M +$711K $2.13 38
2019 Q2 155K $1.54K -$443K $2.68 3
2019 Q1 2.6M $12M +$11.5M $4.92 38
2018 Q4 100K $20K +$20K $0.20 1